Celgene's Multiple Myeloma Triplet Succeeds in Key Phase III Trial Post author:Sam Post published:February 5, 2018 Post category:BioPharma The international clinical study, OPTIMISMM, achieved its primary endpoint. Source: BioSpace You Might Also Like Johnson & Johnson's Imbruvica Scores Expanded FDA Approval for Chronic Graft vs Host Disease August 2, 2017 GlaxoSmithKline Gets Expanded FDA Win for Fluarix January 11, 2018 Johnson & Johnson Forges Peptide Discovery Pact Worth $1.5 Billion With Japanese Biopharma Peptidream April 6, 2017
Johnson & Johnson's Imbruvica Scores Expanded FDA Approval for Chronic Graft vs Host Disease August 2, 2017
Johnson & Johnson Forges Peptide Discovery Pact Worth $1.5 Billion With Japanese Biopharma Peptidream April 6, 2017
